NZ225350A - Labelled or conjugated tpa as a diagnostic or prognostic agent - Google Patents

Labelled or conjugated tpa as a diagnostic or prognostic agent

Info

Publication number
NZ225350A
NZ225350A NZ225350A NZ22535088A NZ225350A NZ 225350 A NZ225350 A NZ 225350A NZ 225350 A NZ225350 A NZ 225350A NZ 22535088 A NZ22535088 A NZ 22535088A NZ 225350 A NZ225350 A NZ 225350A
Authority
NZ
New Zealand
Prior art keywords
tpa
agent
fragment
labelled
tumours
Prior art date
Application number
NZ225350A
Other languages
English (en)
Inventor
Sirkka-Liisa Karonen
Jan Lindgren
Hannu Aronen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NZ225350A publication Critical patent/NZ225350A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Motorcycle And Bicycle Frame (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ225350A 1987-07-08 1988-07-08 Labelled or conjugated tpa as a diagnostic or prognostic agent NZ225350A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873722522 DE3722522A1 (de) 1987-07-08 1987-07-08 Verwendung eines vehikels mit hoher affinitaet zu tumoren

Publications (1)

Publication Number Publication Date
NZ225350A true NZ225350A (en) 1991-07-26

Family

ID=6331118

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ225350A NZ225350A (en) 1987-07-08 1988-07-08 Labelled or conjugated tpa as a diagnostic or prognostic agent

Country Status (13)

Country Link
EP (1) EP0298436B1 (enrdf_load_html_response)
JP (1) JPH01125331A (enrdf_load_html_response)
KR (1) KR890001508A (enrdf_load_html_response)
AT (1) ATE81473T1 (enrdf_load_html_response)
AU (1) AU623080B2 (enrdf_load_html_response)
DE (2) DE3722522A1 (enrdf_load_html_response)
DK (1) DK167561B1 (enrdf_load_html_response)
ES (1) ES2046244T3 (enrdf_load_html_response)
FI (1) FI883177L (enrdf_load_html_response)
GR (1) GR3006404T3 (enrdf_load_html_response)
NO (1) NO883040L (enrdf_load_html_response)
NZ (1) NZ225350A (enrdf_load_html_response)
ZA (1) ZA884870B (enrdf_load_html_response)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA831399B (en) * 1982-03-05 1984-02-29 Health Lab Service Board New fibrinolytic enzymes and methods for their production and pharmaceutical compositions containing them
US4663146A (en) * 1983-07-29 1987-05-05 Codon Genetic Engineering Laboratories Methods and compositions for the diagnosis of bloodclots using plasminogen activator

Also Published As

Publication number Publication date
FI883177A7 (fi) 1989-01-09
ES2046244T3 (es) 1994-02-01
JPH01125331A (ja) 1989-05-17
DE3875290D1 (de) 1992-11-19
EP0298436A3 (en) 1990-01-17
KR890001508A (ko) 1989-03-27
FI883177A0 (fi) 1988-07-04
ATE81473T1 (de) 1992-10-15
AU1889588A (en) 1989-01-12
DE3722522A1 (de) 1989-01-19
EP0298436A2 (de) 1989-01-11
FI883177L (fi) 1989-01-09
DK377588A (da) 1989-01-09
DK167561B1 (da) 1993-11-22
NO883040L (no) 1989-01-09
NO883040D0 (no) 1988-07-07
ZA884870B (en) 1989-04-26
DK377588D0 (da) 1988-07-07
AU623080B2 (en) 1992-05-07
GR3006404T3 (enrdf_load_html_response) 1993-06-21
EP0298436B1 (de) 1992-10-14

Similar Documents

Publication Publication Date Title
Riva et al. Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I‐labelled anti‐tenascin monoclonal antibody BC‐2
JP2961173B2 (ja) 血管透過性促進抱合体
KR102574537B1 (ko) 인간화된 안티 칼리크레인-2 항체
Soltay et al. The kinin system of human plasma V. The probable derivation of prekallikrein activator from activated Hageman factor (XIIa)
EP1064005B1 (en) Urokinase plasminogen activator receptor as a target for diagnosis of micrometastases
Guo et al. A novel indium-111-labeled gonadotropin-releasing hormone peptide for human prostate cancer imaging
CA2406882A1 (en) Diagnostic probes and therapeutics targeting upa and upar
Aulbert et al. Lysosomal accumulation of 67Ga-transferrin in malignant tumors in relation to their growth rate
AU623080B2 (en) Use of an agent with a high affinity for tumours
DE69018361T2 (de) Phosphorylierte plasminogenaktivatoren.
ES2880682T3 (es) Anticuerpos anti PSA (5A10) humanizados
JP2003523400A (ja) 癌治療用および画像化用ｐａｉ−２接合体
US7625868B2 (en) Methods and compositions for inhibiting angiogenesis
CN114558122A (zh) 放射核素标记的过氧化氢酶及其应用
US6896870B1 (en) Diagnostic probes and therapeutics targeting uPA and uPAR
EP0487594A1 (en) REAGENT FOR DETECTION OF FIBRINOLYTIC ACTIVITY.
Mariani et al. Tissue distribution of radiolabeled anti-CEA monoclonal antibodies in man
US12441808B2 (en) Antibody polypeptides and uses thereof
GOTO et al. Tumor accumulation of D-selenomethionine-75Se in tumor-bearing mice
AU594496B2 (en) The use of monoclonal antibodies for the therapy of tumors
Hierowski et al. An inhibitor of urokinase and tissue plasminogen activators in Dunning R3327H prostate tumors of rats treated with D-Trp6-LH-RH
Girard Therapeutic efficacy of intralesional 131I-labelled hyaluronectin in grafted human glioblastoma
Chopra KK (DOTA)
Minamino et al. High urinary hydroxyproline excretion in patients with advanced head and neck cancer
CN113557297A (zh) 具有抗肿瘤活性的肽